LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Gene Therapy of the Central Nervous System: From Bench to Bedside
- 1st Edition - November 11, 2005
- Editors: Michael G. Kaplitt, Matthew During
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 4 1 5 6 9 6 - 8
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 4 5 4 3 7 - 5
Few areas of biomedical research provide greater opportunities for radically new therapies for devastating diseases that have evaded treatment so far than gene therapy. This is… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteFew areas of biomedical research provide greater opportunities for radically new therapies for devastating diseases that have evaded treatment so far than gene therapy. This is particularly true for the brain and nervous system, where gene transfer has become a key technology for basic research and has recently been translated to human therapy in several landmark clinical trials. Gene Therapy of the Central Nervous System: From Bench to Bedside represents the first definitive volume on this subject. Edited by two pioneers of neurological gene therapy, this volume contains contributions by leaders who helped create this field and are expanding the promise of gene therapy for the future of basic and clinical neuroscience. Drawing upon this extensive collective experience, this book provides clear and informative reviews on a variety of subjects of interest to anyone exploring or using gene therapy for neurobiological applications in research and clinical praxis.
* Presents gene transfer technologies with particular emphases upon novel vehicles, immunological issues and the role of gene therapy in stem cells
* Discusses preclinical areas that are likely to translate into clinical studies in the near future, including epilepsy, pain and amyotrophic lateral sclerosis
* Includes "insider" information on technological and regulatory issues which can often limit effective translation of even the most promising idea into clinical use
* Discusses preclinical areas that are likely to translate into clinical studies in the near future, including epilepsy, pain and amyotrophic lateral sclerosis
* Includes "insider" information on technological and regulatory issues which can often limit effective translation of even the most promising idea into clinical use
Neuroscientists, geneticists, molecular biologists, pharmaceutical companies
SECTION I. GENE TRANSFER TECHNOLOGY AND REGULATORY ISSUES
1. Design and optimization of expression cassettes including promoter choice and regulatory lements
2. Identification of Novel AAV Serotypes for Use as Vectors
3. HSV amplicon vectors for gene delivery to the nervous system
4. Influence of the immune system on CNS gene transfer
5. Targeted induction of endogenous neural stem and progenitor cells: A new strategy for gene therapy of neurological disease
6. Neurosurgical Targeting, Delivery and Infusion of Gene Therapy Agents in the Brain
7. Gene Transfer for Neurological Disease: Agencies, Policies and Process
SECTION II. GENE THERAPY FOR DEGENERATIVE AND FUNCTIONAL DISORDERS
8. Gene therapy for Parkinson’s disease
9. Non human primate models for testing gene therapy for neurodegenerative disorders
10. Delivery of Molecular Therapeutics into the CNS and their Distribution within the Brain
11. Gene therapy for CNS diseases using intrabodies
12. Gene therapy for epilepsy
SECTION IIII. PSYCHIATRIC AND BEHAVIORAL GENE THERAPY
13. Genetic manipulation of learning and memory
14. Psychiatric applications of viral vectors
15. Use of viral vectors to influencebehavior
SECTION IV. GENE THERAPY FOR PAIN AND SPINAL CORD DISEASES
16. Herpes simplex vector mediated gene transfer to the peripheral nervous system for the treatment of polyneuropathy and chronic pain
17. Characterization of pain receptors in the spinal cord using a viral vector for spatial-temportal gene targeting
18. Viral vector mediated gene therapy of pain
19. VEGF, an angiogenic factor with neurotrophic activity, useful for treatment of ALS?
20. Viral Vector Axonal Uptake and Retrograde Transport: Mechanisms and Applications
21. Gene therapy for spinal cord injury
V. GENE THERAPY FOR BRAIN TUMORS AND NEUROGENETIC DISEASES
22. Prodrug-Activation Gene Therapy
23. Clinical trials of gene therapy for Canavan Disease
24. Gene therapy for the late infantile form of Batten disease
25. Molecular Imaging of Gene Therapy for Neurogenetic Diseases
1. Design and optimization of expression cassettes including promoter choice and regulatory lements
2. Identification of Novel AAV Serotypes for Use as Vectors
3. HSV amplicon vectors for gene delivery to the nervous system
4. Influence of the immune system on CNS gene transfer
5. Targeted induction of endogenous neural stem and progenitor cells: A new strategy for gene therapy of neurological disease
6. Neurosurgical Targeting, Delivery and Infusion of Gene Therapy Agents in the Brain
7. Gene Transfer for Neurological Disease: Agencies, Policies and Process
SECTION II. GENE THERAPY FOR DEGENERATIVE AND FUNCTIONAL DISORDERS
8. Gene therapy for Parkinson’s disease
9. Non human primate models for testing gene therapy for neurodegenerative disorders
10. Delivery of Molecular Therapeutics into the CNS and their Distribution within the Brain
11. Gene therapy for CNS diseases using intrabodies
12. Gene therapy for epilepsy
SECTION IIII. PSYCHIATRIC AND BEHAVIORAL GENE THERAPY
13. Genetic manipulation of learning and memory
14. Psychiatric applications of viral vectors
15. Use of viral vectors to influencebehavior
SECTION IV. GENE THERAPY FOR PAIN AND SPINAL CORD DISEASES
16. Herpes simplex vector mediated gene transfer to the peripheral nervous system for the treatment of polyneuropathy and chronic pain
17. Characterization of pain receptors in the spinal cord using a viral vector for spatial-temportal gene targeting
18. Viral vector mediated gene therapy of pain
19. VEGF, an angiogenic factor with neurotrophic activity, useful for treatment of ALS?
20. Viral Vector Axonal Uptake and Retrograde Transport: Mechanisms and Applications
21. Gene therapy for spinal cord injury
V. GENE THERAPY FOR BRAIN TUMORS AND NEUROGENETIC DISEASES
22. Prodrug-Activation Gene Therapy
23. Clinical trials of gene therapy for Canavan Disease
24. Gene therapy for the late infantile form of Batten disease
25. Molecular Imaging of Gene Therapy for Neurogenetic Diseases
- No. of pages: 370
- Language: English
- Edition: 1
- Published: November 11, 2005
- Imprint: Academic Press
- Paperback ISBN: 9780124156968
- eBook ISBN: 9780080454375
MK
Michael G. Kaplitt
Affiliations and expertise
New York Hospital, Cornell University Medical College and Laboratory of Neurobiology and Behavior, The Rockefeller University, New York, U.S.A.Read Gene Therapy of the Central Nervous System: From Bench to Bedside on ScienceDirect